A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Study ◽

Group Trial ◽

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Cited By ~ 3

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Acta Oncologica ◽

10.1080/0284186x.2020.1851045 ◽

2020 ◽

pp. 1-8

Author(s):

Anne Sofie Brems-Eskildsen ◽

Søren Linnet ◽

Hella Danø ◽

Adam Luczak ◽

Peter Michael Vestlev ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Oral Capecitabine ◽

Phase 2 Study ◽

Metronomic Treatment ◽

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3288216 ◽

2018 ◽

Author(s):

Fei Ma ◽

Quchang Ouyang ◽

Binghe Xu ◽

Wei Li ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Previously Treated

Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study

10.1158/1538-7445.sabcs16-s2-05 ◽

2017 ◽

Cited By ~ 6

Author(s):

HS Han ◽

V Diéras ◽

ME Robson ◽

M Palácová ◽

PK Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

10.1158/1538-7445.sabcs19-p5-14-05 ◽

2020 ◽

Author(s):

Elgene Lim ◽

Frances Boyle ◽

Meena Okera ◽

Sherene Loi ◽

Sema Sezgin Goksu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Previously Treated ◽

The Impact ◽

134P Safety and efficacy of eribulin and trastuzumab in anti-HER2 therapy pretreated patients with HER2-positive metastatic breast cancer: A Japanese multicenter phase 2 study (SBP-04 study)

Annals of Oncology ◽

10.1093/annonc/mdw577.017 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

T. Shien ◽

M. Ikeda ◽

S. Ohtani ◽

F. Hara ◽

M. Takahashi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Safety And Efficacy ◽

Multicenter Phase ◽

Phase 2 Study ◽

Pretreated Patients

134P Safety and efficacy of eribulin and trastuzumab in anti-HER2 therapy pretreated patients with HER2-positive metastatic breast cancer: A Japanese multicenter phase 2 study (SBP-04 study)

Annals of Oncology ◽

10.1016/s0923-7534(21)00292-1 ◽

2016 ◽

Vol 27 ◽

pp. ix39-ix40

Author(s):

T. Shien ◽

M. Ikeda ◽

S. Ohtani ◽

F. Hara ◽

M. Takahashi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Safety And Efficacy ◽

Multicenter Phase ◽

Phase 2 Study ◽

Pretreated Patients

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70432-1 ◽

2013 ◽

Vol 14 (1) ◽

pp. 64-71 ◽

Cited By ~ 368

Author(s):

Thomas Bachelot ◽

Gilles Romieu ◽

Mario Campone ◽

Véronique Diéras ◽

Claire Cropet ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Phase 2 ◽

Single Group ◽

Her2 Positive ◽

Phase 2 Study

Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects withBRCA1orBRACA2mutation and metastatic breast cancer

10.1158/0008-5472.sabcs12-ot2-3-07 ◽

2012 ◽

Author(s):

SJ Isakoff ◽

S Pulhalla ◽

SP Shepherd ◽

N Falotico ◽

B Kaufman ◽

...

Keyword(s):

Breast Cancer ◽

Parp Inhibitor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc)

Annals of Oncology ◽

10.1016/s0923-7534(19)65752-2 ◽

2012 ◽

Vol 23 ◽

pp. ii43 ◽

Cited By ~ 2

Author(s):

A. Awada ◽

S. Chan ◽

G.H.M. Jerusalem ◽

R.E. Coleman ◽

M.T. Huizing ◽

...

Keyword(s):

Breast Cancer ◽

Antitumor Activity ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽